Motolimod

Drug Celgene Corporation
Total Payments
$20,135
Transactions
8
Doctors
7
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $19,050 1 0
2017 $1,085 7 7

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $19,050 1 94.6%
Food and Beverage $1,085 7 5.4%

Payments by Type

Research
$19,050
1 transactions
General
$1,085
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Phase Ib Motolimod Pre Surgerical Biomarker SCCHN (VTX-2337-HN-001) (BMS Study Number: CA075-P01) (VTX-2337-HN-001) Celgene Corporation $19,050 0

Top Doctors Receiving Payments for Motolimod

Doctor Specialty Location Total Records
Unknown Saint Louis, MO $19,050 1
, MD Medical Oncology Saint Louis, MO $155.05 1
, M.D Interventional Cardiology Philadelphia, PA $155.05 1
, MD Otolaryngology Pittsburgh, PA $155.05 1
, MD Medical Oncology Tampa, FL $155.05 1
Everett Vokes Hematology & Oncology Burr Ridge, IL $155.05 1
, MD Medical Oncology Boston, MA $155.05 1
, MD Medical Oncology Charlotte, NC $155.05 1

About Motolimod

Motolimod is a drug associated with $20,135 in payments to 7 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2017 to 2019. In 2019, $19,050 was paid across 1 transactions to 0 doctors.

The most common payment nature for Motolimod is "Unspecified" ($19,050, 94.6% of total).

Motolimod is associated with 1 research study, including "Phase Ib Motolimod Pre Surgerical Biomarker SCCHN (VTX-2337-HN-001) (BMS Study Number: CA075-P01) (VTX-2337-HN-001)" ($19,050).